Insider Transactions in Q1 2023 at Ironwood Pharmaceuticals Inc (IRWD)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
46,129
-5.19%
|
$461,290
$10.67 P/Share
|
|
Mar 15
2023
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,438
+1.52%
|
-
|
|
Mar 15
2023
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,677
+1.63%
|
-
|
|
Mar 08
2023
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,620
+20.99%
|
-
|
|
Mar 08
2023
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,595
+21.31%
|
-
|
|
Mar 08
2023
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,502
+24.74%
|
-
|
|
Mar 08
2023
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,668
+10.4%
|
-
|
|
Mar 08
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
69,869
+17.41%
|
-
|
|
Mar 08
2023
|
Andrew Davis SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,236
+24.76%
|
-
|
|
Mar 08
2023
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,236
+32.72%
|
-
|
|
Mar 03
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,756
-4.95%
|
$371,316
$11.22 P/Share
|
|
Feb 28
2023
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,049
-3.0%
|
$33,539
$11.31 P/Share
|
|
Feb 28
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
9,854
-1.83%
|
$108,394
$11.31 P/Share
|
|
Feb 28
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,227
-2.2%
|
$343,497
$11.31 P/Share
|
|
Feb 28
2023
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,429
-2.51%
|
$191,719
$11.31 P/Share
|
|
Feb 28
2023
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,822
-1.19%
|
$20,042
$11.31 P/Share
|
|
Feb 28
2023
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,415
-2.49%
|
$37,565
$11.31 P/Share
|
|
Feb 27
2023
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,929
-2.8%
|
$32,219
$11.41 P/Share
|
|
Feb 27
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
9,468
-1.7%
|
$104,148
$11.41 P/Share
|
|
Feb 27
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,004
-2.03%
|
$330,044
$11.41 P/Share
|
|
Feb 27
2023
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
16,746
-2.3%
|
$184,206
$11.41 P/Share
|
|
Feb 27
2023
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,751
-1.13%
|
$19,261
$11.41 P/Share
|
|
Feb 27
2023
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,282
-2.34%
|
$36,102
$11.41 P/Share
|
|
Jan 17
2023
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,145
+3.9%
|
-
|
|
Jan 17
2023
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,087
+4.7%
|
-
|
|
Jan 17
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
14,663
+4.96%
|
-
|
|
Jan 05
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
110,962
-13.48%
|
$1,331,544
$12.07 P/Share
|
|
Jan 05
2023
|
Thomas A Mccourt Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110,962
+11.88%
|
$1,220,582
$11.65 P/Share
|